Join companies like...
20Med Therapeutics - Abbott - Asahi Kasei - BalinBac Therapeutics - BIOASTER - BioRN - Boehringer Ingelheim - Cipla - Debiopharm - Dechra - Eligo Bioscience - EMD Serono - Eurocine Vaccines - Exopharm - Fortress Biotech - Galen Pharma - Holy Stone Healthcare - IDBiologics - Immuno Research - Italfarmaco - Johnson & Johnson - Juvabis - Kaken - Madam Therapeutics - MedinCell - Merck - Microbiotix - MGB Biopharma - MiCAN Technologies - Mundipharma - NEUWAY Pharma - Novartis - Oncodesign - Pinetree Therapeutics - Protinhi Therapeutics - Roche - Santen - Selva Therapeutics - Serimmune - SIWA Therapeutics - Valneva - Visterra - Zambon
Plenary Session: Overcoming Challenges in Antibiotic Development
Webinar: Infectious Diseases Event Preview & Virtual Partnering Platform Demo
“At Eurocine Vaccines we are focusing on new solutions to combat infectious diseases. We are delighted to come to Infectious Diseases Virtual Partnering and share the progress of our chlamydia vaccine candidate. The targeted one-on-one meetings will provide an excellent setting for us to identify the best future license partners for this project and to find new, innovative vaccine candidates in our endeavors to expand the portfolio.”
“We at Protinhi Therapeutics are focusing on novel antivirals to combat infectious diseases, specifically dengue and COVID-19. We are excited to come to Infectious Diseases Virtual Partnering on 2-4 December 2020. This targeted meeting will provide the best setting for us to identify the best partners to work side by side to speed up our developments through investments and R&D collaborations.”
Companies profile
Attendees profile
Asset phase
Why participate?
Find potential R&D collaborations or assets available for in-licensing/acquisition
Identify partners with research solutions such as high throughput screening tools, clinical research capacity, or animal models
Secure funding from new investors or find licensing partners for your portfolio
Discover new diagnostics, biomarkers, adjuvants, carrier systems or technologies
Who will attend?
The event is open to any organization that provides assets, products, knowledge or technologies that can help advance the infectious diseases pipelines.
The deployment of successful solutions requires the engagement and implication of multiple stakeholders such as:
Business development, licencing, and scouting executives from the biopharma industry
Biotechs focused on infectious diseases
Early stage researchers from academia, incubators, or research foundations
Companies focusing on infectious diseases related diagnostics or biological markers
Tech transfer offices
Companies providing research tools, models or services needed for infectious diseases R&D
